Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - TACC3 FGFR2 V565F |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - TACC3 FGFR2 V565F | intrahepatic cholangiocarcinoma | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) treatment reduced viability of cells derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2 V565F in the context of FGFR2-TACC3 fusion in culture (PMID: 33741397). | 33741397 | |
FGFR2 - TACC3 FGFR2 V565F | intrahepatic cholangiocarcinoma | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Truseltiq (infigratinib) did not inhibit growth of cells derived from a TP53-null mouse liver tumoroid expressing FGFR2 V565F in the context of FGFR2-TACC3 fusion in culture (PMID: 33741397). | 33741397 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|